Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Drug coating composition for ureteral stent, preparation method and application thereof

The technology of drug coating and composition is applied in the field of drug coating composition of ureteral stent and its preparation field, which can solve the problems of ununiform control of drug release, poor curative effect, etc. absorption effect

Active Publication Date: 2019-02-01
PUYI (SHANGHAI) BIOTECHNOLOGY CO LTD
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This method also has the defect that the drug release cannot be uniformly controlled, and the curative effect is poor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug coating composition for ureteral stent, preparation method and application thereof
  • Drug coating composition for ureteral stent, preparation method and application thereof
  • Drug coating composition for ureteral stent, preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] The drug coating composition provided by this embodiment includes the following components in parts by weight

[0072]

[0073] Dissolve rapamycin, puerarin, formoterol, dexamethasone, mallow seeds, light bamboo leaves, imperata root and plantain seed (the mass ratio of the four natural products is the same) in water according to the proportion, and then mix the Proportional amounts of polyvinylpyrrolidone and sorbitol are added to water, mixed and stirred at 50° C. to form a uniform mixed solution to obtain a drug coating composition.

Embodiment 2

[0075] The drug coating composition provided by this embodiment includes the following components in parts by weight

[0076]

[0077] Rapamycin, puerarin, formoterol, triclosan, mallow seed, light bamboo leaf and sea gold sand (three kinds of natural products with the same mass ratio) were dissolved in ethanol according to the ratio, and then the ratio of poly Add vinylpyrrolidone and xylitol to ethanol, mix and stir at 60° C. to form a uniform mixed solution to obtain a drug coating composition.

Embodiment 3

[0079] The drug coating composition provided by this embodiment includes the following components in parts by weight

[0080]

[0081] Dissolve rapamycin, puerarin, formoterol, rifampicin, dendrobium, light bamboo leaf and Haijinsha (three kinds of natural products with the same mass ratio) in isopropanol according to the ratio, and then the ratio of poly Add oxyethylene sorbitan monostearate and xylitol into isopropanol, mix and stir at 40° C. to form a uniform mixed solution to obtain a drug coating composition.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a drug coating composition for a ureteral stent, a preparation method and application thereof. The drug coating composition comprises the following components by weight: 0.3-1.3parts of rapamycin, 0.02-0.09 part of puerarin, 0.01-0.05 part of formoterol, 0.2-1.5 parts of an anti-infective drug, 2-6 parts of a natural product, 1-2 parts of a hydrophilic polymer, 1.3-4.5 parts of an additive and 20-90 parts of a solvent. Through rational collocation of the three components rapamycin, puerarin and anti-infective drug, the drug coating composition provided by the inventionnot only has good ureteral dilatation effect, but also has the effects of bacteriostasis, inflammation resistance and treatment of ureteral injury, at the same time through the regulation of the hydrophilic polymer and the additive, the composition has a long-acting sustained release effect, can achieve a more lasting curative effect, also provides a new strategy for research and development of new drugs, and has good application prospects.

Description

technical field [0001] The invention belongs to the field of medical devices, and relates to a drug coating composition for ureteral stents, a preparation method and application thereof. Background technique [0002] The drug coating on the stent is to coat the drug directly or mixed with the polymer matrix on the surface of the stent, so that the stent becomes a local drug release system, which can increase the local concentration and action time of the therapeutic drug on the one hand, and on the other hand Toxic and side effects caused by systemic administration can be avoided. [0003] According to clinical statistics, ureteral stenosis is a common long-term complication after ureteral calculus surgery. Whether it is open stone removal, laparoscopic stone removal, or endoscopic lithotripsy, the incidence of ureteral stricture is about 10%. With the development of endourology, the incidence of surgery-induced ureteral injury has increased significantly. The ureter injur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61K31/436A61K31/137A61K31/63A61K31/496A61K31/573A61K31/155A61K31/075A61K31/165A61P13/02A61P31/02A61P31/04A61P29/00A61K36/899A61K35/57
CPCA61F2/82A61F2310/0097A61K31/075A61K31/137A61K31/155A61K31/165A61K31/352A61K31/436A61K31/496A61K31/573A61K31/63A61K35/57A61K36/12A61K36/185A61K36/68A61K36/8984A61K36/899A61P13/02A61P29/00A61P31/02A61P31/04A61K2300/00
Inventor 夏佩佩魏征谢建
Owner PUYI (SHANGHAI) BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com